353 related articles for article (PubMed ID: 28326775)
21. Pocketome of human kinases: prioritizing the ATP binding sites of (yet) untapped protein kinases for drug discovery.
Volkamer A; Eid S; Turk S; Jaeger S; Rippmann F; Fulle S
J Chem Inf Model; 2015 Mar; 55(3):538-49. PubMed ID: 25557645
[TBL] [Abstract][Full Text] [Related]
22. KiSSim: Predicting Off-Targets from Structural Similarities in the Kinome.
Sydow D; Aßmann E; Kooistra AJ; Rippmann F; Volkamer A
J Chem Inf Model; 2022 May; 62(10):2600-2616. PubMed ID: 35536589
[TBL] [Abstract][Full Text] [Related]
23. Reactive Chemical Probes: Beyond the Kinase Cysteinome.
Jones LH
Angew Chem Int Ed Engl; 2018 Jul; 57(30):9220-9223. PubMed ID: 29644769
[TBL] [Abstract][Full Text] [Related]
24. Exploration and Comparison of the Geometrical and Physicochemical Properties of an αC Allosteric Pocket in the Structural Kinome.
Sturm N; Tinivella A; Rastelli G
J Chem Inf Model; 2018 May; 58(5):1094-1103. PubMed ID: 29697977
[TBL] [Abstract][Full Text] [Related]
25. Electrophilic fragment-based design of reversible covalent kinase inhibitors.
Miller RM; Paavilainen VO; Krishnan S; Serafimova IM; Taunton J
J Am Chem Soc; 2013 Apr; 135(14):5298-301. PubMed ID: 23540679
[TBL] [Abstract][Full Text] [Related]
26. Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.
Kwarcinski FE; Brandvold KR; Phadke S; Beleh OM; Johnson TK; Meagher JL; Seeliger MA; Stuckey JA; Soellner MB
ACS Chem Biol; 2016 May; 11(5):1296-304. PubMed ID: 26895387
[TBL] [Abstract][Full Text] [Related]
27. Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.
Lu X; Smaill JB; Patterson AV; Ding K
J Med Chem; 2022 Jan; 65(1):58-83. PubMed ID: 34962782
[TBL] [Abstract][Full Text] [Related]
28. Reactivities of the Front Pocket N-Terminal Cap Cysteines in Human Kinases.
Liu R; Zhan S; Che Y; Shen J
J Med Chem; 2022 Jan; 65(2):1525-1535. PubMed ID: 34647463
[TBL] [Abstract][Full Text] [Related]
29. Construction of Covalent Bisubstrate Inhibitor of Protein Kinase Reacting with Cysteine Residue at Substrate-Binding Site.
Sõrmus T; Lavogina D; Teearu A; Enkvist E; Uri A; Viht K
J Med Chem; 2022 Aug; 65(16):10975-10991. PubMed ID: 35960538
[TBL] [Abstract][Full Text] [Related]
30. Cysteine-targeted Irreversible Inhibitors of Tyrosine Kinases and Key Interactions.
Hu C; Dong X
Curr Med Chem; 2019; 26(31):5811-5824. PubMed ID: 30009703
[TBL] [Abstract][Full Text] [Related]
31. Modeling conformational flexibility of kinases in inactive states.
Schwarz D; Merget B; Deane C; Fulle S
Proteins; 2019 Nov; 87(11):943-951. PubMed ID: 31168936
[TBL] [Abstract][Full Text] [Related]
32. Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases.
Zhu Y; Hu X
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296718
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive structural and functional characterization of the human kinome by protein structure modeling and ligand virtual screening.
Brylinski M; Skolnick J
J Chem Inf Model; 2010 Oct; 50(10):1839-54. PubMed ID: 20853887
[TBL] [Abstract][Full Text] [Related]
34. DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors.
Ung PM; Schlessinger A
ACS Chem Biol; 2015 Jan; 10(1):269-78. PubMed ID: 25420233
[TBL] [Abstract][Full Text] [Related]
35. Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines.
Toral-Barza L; Zhang WG; Huang X; McDonald LA; Salaski EJ; Barbieri LR; Ding WD; Krishnamurthy G; Hu YB; Lucas J; Bernan VS; Cai P; Levin JI; Mansour TS; Gibbons JJ; Abraham RT; Yu K
Mol Cancer Ther; 2007 Nov; 6(11):3028-38. PubMed ID: 17989320
[TBL] [Abstract][Full Text] [Related]
36. ZNL0325, a Pyrazolopyrimidine-Based Covalent Probe, Demonstrates an Alternative Binding Mode for Kinases.
Li Z; Lu W; Beyett TS; Ficarro SB; Jiang J; Tse J; Kim AY; Marto JA; Che J; Jänne PA; Eck MJ; Zhang T; Gray NS
J Med Chem; 2024 Feb; 67(4):2837-2848. PubMed ID: 38300264
[TBL] [Abstract][Full Text] [Related]
37. Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα.
Borsari C; Keles E; McPhail JA; Schaefer A; Sriramaratnam R; Goch W; Schaefer T; De Pascale M; Bal W; Gstaiger M; Burke JE; Wymann MP
J Am Chem Soc; 2022 Apr; 144(14):6326-6342. PubMed ID: 35353516
[TBL] [Abstract][Full Text] [Related]
38. What Makes a Kinase Promiscuous for Inhibitors?
Hanson SM; Georghiou G; Thakur MK; Miller WT; Rest JS; Chodera JD; Seeliger MA
Cell Chem Biol; 2019 Mar; 26(3):390-399.e5. PubMed ID: 30612951
[TBL] [Abstract][Full Text] [Related]
39. Cross-reactivity virtual profiling of the human kinome by X-react(KIN): a chemical systems biology approach.
Brylinski M; Skolnick J
Mol Pharm; 2010 Dec; 7(6):2324-33. PubMed ID: 20958088
[TBL] [Abstract][Full Text] [Related]
40. The resistance tetrad: amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles.
Bailey FP; Andreev VI; Eyers PA
Methods Enzymol; 2014; 548():117-46. PubMed ID: 25399644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
